Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Step by step instructions to Pick the Right Sunlight powered charger Type for Your Home - 210 Famous Frozen yogurt Flavors All over The Planet
- 3Pope Leo XIV calls for urgent climate action and says God’s creation is 'crying out'
- 4Ocean side Objections: Staggering Waterfront Breaks
- 5American tourists left stranded in the Caribbean following flight cancellations after airspace closed for Maduro operation
- Figure out How to Protect Your Gold Venture from Unpredictability
- Iran war drives global fertilizer prices up, raising food cost fears
- Understanding Successful Compromise Standards to Cultivate Agreeable Connections
- 6 Modest and Strong Tire Brands
- West Antarctica’s history of rapid melting foretells sudden shifts in continent’s ‘catastrophic’ geology
- The Manual for Electric Vehicles that will be hot dealers in 2023
- Lahav 433 head Asst.-Ch. Meni Benjamin named as police officer investigated for breach of trust
- This ‘CSI: Miami’ star spent years solving crimes on TV. Then she became the target of one herself.
- Man threatens attack on German high-speed train, 12 lightly injured
